



(51) International Patent Classification:

C12N 15/88 (2006.01) A61K 48/00 (2006.01)
C12N 15/113 (2010.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/SG2023/050161

(22) International Filing Date:

13 March 2023 (13.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202202517W 11 March 2022 (11.03.2022) SG

(71) Applicants: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). **NANYANG TECHNOLOGICAL UNIVERSITY** [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG). **CARMINE THERAPEUTICS PTE LTD** [SG/SG]; 3 Biopolis Drive, Synapse #06-11, Singapore 138623 (SG).

(72) Inventors: **LE, Thi Nguyet Minh**; c/o National University of Singapore, Yong Loo Lin School of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **PENG, Boya**; c/o National University of Singapore, Yong Loo Lin School of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **PHUNG, Cao Dai**; c/o National University of Singapore, Yong Loo Lin School of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **LUO, Dahai**; c/o Nanyang Technological University, 50 Nanyang Av-

enue, Singapore 639798 (SG). **YEO, Wee Yeh Ronne**; c/o Carmine Therapeutics Pte Ltd, 3 Biopolis Drive, Synapse #06-11, Singapore 138623 (SG). **NGUYEN, Mai Trinh**; c/o Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG).

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road, Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: VESICLE-BASED COMPOSITIONS AND USES THEREOF




Fig. 6

(57) Abstract: Disclosed are vesicle-based compositions and uses thereof. The composition comprising a vesicle, such as a red blood cell-derived extracellular vesicle (RBCEV), for delivery of a retinoic acid inducible gene I receptor (RIG-I) agonist to a cell. Also disclosed are methods for treating diseases by administering the vesicle-based compositions.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*